abemaciclib






45 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 24795392 Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014 Jul 1 1
2 24850847 Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res 2014 Jul 15 4
3 24919854 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 2014 Oct 4
4 25122067 The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther 2014 Oct 7
5 26726315 Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. Int J Cancer Clin Res 2015 2
6 26896604 Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med 2016 Jan 1
7 26909611 The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget 2016 Mar 22 6
8 26995305 Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res 2016 May 1
9 27312735 Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol 2016 Aug 1
10 27493615 Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel) 2016 Jun 1
11 27748766 Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 2017 Apr 20 2
12 27816545 Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol 2017 Jan 15 11
13 29074254 Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors. Bioorg Med Chem Lett 2017 Dec 1 1
14 29125595 Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer. Med Lett Drugs Ther 2017 Nov 6 2
15 29429832 Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. Bioorg Med Chem Lett 2018 Mar 1 1
16 29716919 Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer <i>In Vitro</i> and <i>In Vivo</i>. Clin Cancer Res 2018 Aug 15 1
17 30014236 Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature. Strahlenther Onkol 2018 Nov 1
18 30165341 Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors. Eur J Med Chem 2018 Sep 5 1
19 31464525 Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. Future Oncol 2019 Oct 2
20 31530780 [Pharmacological Effects of CDK4 &amp; 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer]. Gan To Kagaku Ryoho 2019 Sep 1
21 31875784 Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6. Curr Drug Res Rev 2019 1
22 32536013 Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020 Sep 2
23 32582803 Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells. Rep Biochem Mol Biol 2020 Jan 1
24 32710211 MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol 2021 Mar 2
25 32781837 Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Future Oncol 2020 Nov 1
26 32789591 Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat 2020 Nov 2
27 32835580 Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against <i>RET</i>-fusion-positive non-small cell lung cancer cells. Cancer Biol Ther 2020 Sep 1 1
28 32899250 PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells. Cancers (Basel) 2020 Sep 3 2
29 33116117 Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma. Cell Death Dis 2020 Oct 28 3
30 33280445 Preclinical discovery and development of abemaciclib used to treat breast cancer. Expert Opin Drug Discov 2021 May 3
31 33330839 Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacol Transl Sci 2020 Dec 11 1
32 33686753 Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 &amp; 3 trials. Cancer Sci 2021 Jun 1
33 33867426 Molecular Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer in Clinical Practice. J Nippon Med Sch 2022 Mar 11 1
34 33968263 ESMO 2020: highlights in breast cancer. Memo 2021 Apr 30 4
35 34407567 Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology 2022 Jan 1
36 34425869 Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Res 2021 Aug 23 1
37 34593430 Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations. Anticancer Res 2021 Oct 2
38 34657059 [A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole]. Gan To Kagaku Ryoho 2021 Oct 2
39 34690920 Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature. Front Endocrinol (Lausanne) 2021 1
40 35094535 How we treat HR-positive, HER2-negative early breast cancer. Future Oncol 2022 Mar 1
41 35121623 Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. Clin Cancer Res 2022 Apr 14 1
42 35135362 Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer. Ann Pharmacother 2022 Feb 8 2
43 35157829 Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol 2022 Mar 1
44 35169388 Update Breast Cancer 2021 Part 4 - Prevention and Early Stages. Geburtshilfe Frauenheilkd 2022 Feb 1
45 35475118 An <i>in silico</i> approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors. Saudi J Biol Sci 2022 Jun 1